"Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash. The purchase price is $10.4 billion, or $9.7 billion net of estimated Onyx cash, $125 per share"
Onyx at the time had 3 partnered assets and a few compounds in clinical development. Still sounds like KYPROLIS is the main target they were after and spent $10b to get it despite only bringing in revenues of $1b recently.
According to Amgens 2020 financials it took in total revenues of $1.065B, a 2% increase on 2019 at $1.044B
Interestingly this article is reporting a slight decline of the overall market due to Patent expiry among other things. If Zantrene extends the ability for them to take market share until 2041, what is that worth to a company like Amgen?
"Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.045(2.73%) |
Mkt cap ! $272.2M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.67 | $1.51 | $214.0K | 133.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 708 | $1.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 500 | 1 |
View Market Depth
| Last trade - 15.50pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.60 |
Change
-0.045 ( 2.74 %) |
||||
| Open | High | Low | Volume | ||
| $1.66 | $1.68 | $1.52 | 19707 | ||
| Last updated 15.48pm 04/06/2024 ? | |||||
| RAC (ASX) Chart |